Antibody-drug conjugates (ADCs): all 1,111 studies that test it

Page 10 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.

• Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04754191Phase 2
• Phase II Study of T-DX in HER2-positive Breast Cancer Brain MetastasesCompletedNCT04752059Phase 2
• Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerActive, not recruitingNCT04733118Phase 2
• Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Phase 3
• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3
• Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple MyelomaActive, not recruitingNCT04680468Phase 2
• Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's TransformationActive, not recruitingNCT04679012Phase 2
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerActive, not recruitingNCT04676477Phase 1
• Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesActive, not recruitingNCT04647916Phase 2
• Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Active, not recruitingNCT04639986Phase 3
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingNCT04622319Phase 3
• A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL AmyloidosisCompletedNCT04617925Phase 2
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04612751Phase 1
• A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 ExpressionActive, not recruitingNCT04610528Early Phase 1
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• Sacituzumab Govitecan in Primary HER2-negative Breast CancerActive, not recruitingNCT04595565Phase 3
• A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCLActive, not recruitingNCT04594798Phase 2
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2
• A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingNCT04556773Phase 1
• A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast CancerActive, not recruitingNCT04538742Phase 1/2
• POLA+BR for Relapsed or Refractory DLBCLWithdrawnNCT04535102Phase 2
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1
• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsActive, not recruitingNCT04482309Phase 2
• Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated LymphomaActive, not recruitingNCT04479267Phase 2
• Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsActive, not recruitingNCT04454437Phase 2
• A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic FunctionWithdrawnNCT04398680Phase 1
• Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04384484Phase 3
• Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)Active, not recruitingNCT04379596Phase 2
• Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell LymphomasWithdrawnNCT04334174Phase 2
• A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract CancerActive, not recruitingNCT04329429Phase 2
• A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT04311034Phase 1/2
• Testing the Biological Effects of DS-8201a on Patients With Advanced CancerActive, not recruitingNCT04294628Phase 1
• Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian CancerActive, not recruitingNCT04274426Phase 2
• A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial CancerStatus unknownNCT04264936Phase 1/2
• A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial CarcinomaActive, not recruitingNCT04251416Phase 2
• Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell LymphomaActive, not recruitingNCT04231877Phase 1/2
• Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT04207190Phase 1
• An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung CancerTerminatedNCT04189614Phase 1
• Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Phase 1/2
• Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsActive, not recruitingNCT04145622Phase 1/2
• Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisCompletedNCT04132960Phase 2
• A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial CancerCompletedNCT04073602Phase 2
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1
• Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.Active, not recruitingNCT04039230Phase 1/2
• Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0CompletedNCT03995706Early Phase 1
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaCompletedNCT03991884Phase 1
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingNCT03971409Phase 2
• Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLActive, not recruitingNCT03962465Phase 1
• Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
• A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid MalignanciesCompletedNCT03913741Phase 1/2
• Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic LeukemiaTerminatedNCT03913559Phase 2
• CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTerminatedNCT03904251Phase 1
• Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaCompletedNCT03900949Phase 1
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic LeukemiaWithdrawnNCT03851081Phase 1/2
• Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03848754Phase 1
• Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial CancerWithdrawnNCT03836157Phase 2
• A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial CancerCompletedNCT03809013Phase 2
• Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminatedNCT03786081Phase 1/2
• T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
• Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17Active, not recruitingNCT03755804Phase 2
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate CancerCompletedNCT03724747Phase 1
• Multi-Center Study of GSK2857916 in Combination With Pomalidomide and DexActive, not recruitingNCT03715478Phase 1/2
• Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell LymphomaCompletedNCT03677154Phase 1/2
• Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeCompletedNCT03672539Phase 2
• Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT03652441Phase 2
• Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic LeukemiaActive, not recruitingNCT03610438Phase 2
• Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsActive, not recruitingNCT03587844Phase 2
• A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2CompletedNCT03556345Phase 2
• Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT03552471Phase 1
• Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
• PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCLCompletedNCT03543813Phase 1/2
• BV After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03540849Phase 2
• Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruitingNCT03539536Phase 2
• An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03533283Phase 1/2
• OPTmizing Advanced Stage HodgkIn LymphoMa patIentS TherapyStatus unknownNCT03527628Phase 2
• A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial CancerCompletedNCT03507166Phase 2
• A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesActive, not recruitingNCT03500380Phase 2/3
• Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With GemcitabineCompletedNCT03496779Phase 2
• MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT03489525Phase 1
• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive, not recruitingNCT03485209Phase 2
• Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)Status unknownNCT03474133Phase 2
• A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedNCT03467373Phase 1
• Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseActive, not recruitingNCT03441061Phase 2
• Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.Status unknownNCT03418558Phase 2
• First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Active, not recruitingNCT03401385Phase 1
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
• A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid TumorsCompletedNCT03311477Phase 1
• Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
• A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial CancerTerminatedNCT03288545Phase 1/2
• A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell LymphomaCompletedNCT03274492Phase 3
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT03260491Phase 1
• Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALLCompletedNCT03249870Phase 2
• Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal CancerStatus unknownNCT03225937Phase 2
• CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.CompletedNCT03217643Phase 2
• Kadcyla In pAtients With bRAin MetastasisWithdrawnNCT03203616Phase 2
• Brentuximab Vedotin in Early Diffuse Cutaneous Systemic SclerosisCompletedNCT03198689Phase 2
• Brentuximab Vedotin and BeEAM High-dose Chemotherapy in LymphomasSuspendedNCT03187210Phase 1/2
• Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast CancerCompletedNCT03153163Phase 1

← Antibody-drug conjugates (ADCs) overview